Associated Papers
Clinical Characteristics of CARD14-Associated Papulosquamous Eruption and Evaluation of Therapeutic Efficacy of Secukinumab.
Zhao X et al.
Journal of Inflammation Research, 2025
Targeting IL-1 controls refractory pityriasis rubra pilaris.
Schmauch E et al.
Science Advances, 2024
38959302 (PubMed )
Supplement: sciadv.ado2365_sm.pdf
Bi-allelic mutation in SEC16B alters collagen trafficking and increases ER stress.
El-Gazzar A et al.
Embo Molecular Medicine, 2023
36916446 (PubMed )
Supplement: EMMM-15-e16834-s012.xlsx › WES_SEC16B_mutant
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.
Aksentijevich I et al.
Nature Reviews. Rheumatology, 2021
Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease.
Mellett M
Cellular Immunology, 2020
CARD14/CARMA2 Signaling and its Role in Inflammatory Skin Disorders.
Zotti T et al.
Frontiers in Immunology, 2018
Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease.
Israel L et al.
Frontiers in Immunology, 2018
Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation.
Takeichi T et al.
The British Journal of Dermatology, 2017
CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis.
Van Nuffel E et al.
The Journal of Investigative Dermatology, 2017
CARD14 Glu138 mutation in familial pityriasis rubra pilaris does not warrant differentiation from familial psoriasis.
Inoue N et al.
The Journal of Dermatology, 2016
Genetic analysis of CARD14 in non-familial pityriasis rubra pilaris: a case series.
Hong JB et al.
Acta Dermato-venereologica, 2014
Familial pityriasis rubra pilaris is caused by mutations in CARD14.
Fuchs-Telem D et al.
American Journal of Human Genetics, 2012
Select a paper to view details